Karen Flynn, Catalent

Q&A: When the pan­dem­ic struck, Catal­en­t's CCO had just joined the team

Karen Fly­nn came aboard Catal­ent’s team just in time.

The com­pa­ny was go­ing through a surge of changes, and she had been brought over from her role as CCO of West Phar­ma­ceu­ti­cal Ser­vices to serve in the same ca­pac­i­ty for the New Jer­sey-based CD­MO. Then a few months lat­er, the pan­dem­ic was in full-force.

Since then, Catal­ent’s been in hy­per-ex­pan­sion mode. In ear­ly May, it ac­quired Promethera’s He­pat­ic Cell Ther­a­py Sup­port SA sub­sidiary and its 32,40-square-foot fa­cil­i­ty in Gos­selies, Bel­gium. Pri­or to that, the com­pa­ny ac­quired Bel­gian CD­MO Del­phi Ge­net­ics, wrapped up the ex­pan­sion of an al­ready-ex­ist­ing site in Madi­son, WI and added an ul­tra-low tem­per­a­ture freez­er part­ner in Ster­ling. As Emer­gent has botched mil­lions of dos­es of As­traZeneca’s vac­cine, the com­pa­ny has swooped in to move that pro­duc­tion to its Mary­land plant as well.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.